Proactive Investors - Run By Investors For Investors

Silence Therapeutics says Iain Ross to return as its chairman and non-executive director with immediate effect

Ross was Silence's chairman from 2005 to 2010 and is currently is non-executive chairman at Kazia Therapeutics Limited, e-Therapeutics PLC and Redx Pharma PLC
Handshake
Silence also announced the appointment of James Ede-Golightly as a non-executive director, and said Stephen Parker will step down from that role

Silence Therapeutics PLC (LON:SLN) shares rose on Thursday following news it has appointed Iain Ross as a non-executive director and its chairman with immediate effect, with the experienced director returning to a role he held from 2005 to 2010.

The AIM-listed group, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, pointed out that Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years.

READ: Silence Therapeutics confirms Dr Rob Quinn as chief financial officer

Currently, it added, he is non-executive chairman at Kazia Therapeutics Limited, e-Therapeutics PLC and Redx Pharma Plc.

Dr. David Horn Solomon, Silence’s chief executive officer commented: “Iain brings with him extensive healthcare and governance experience and I am looking forward to working with him to build significant value for shareholders, patients and their caregivers.”

Incoming chairman Ross added: "I am delighted to be returning to Silence Therapeutics and I look forward to working with David, the new management team and all stakeholders. With a renewed strategy in place and a return to the clinic imminent I believe Silence now represents a fundamentally transformed value proposition and I am excited to work with the team and to bring some stability to the Board to deliver on its potential."

Silence also announced the appointment of James Ede-Golightly as a non-executive director, while it said Stephen Parker will step down from that role, both with immediate effect.

Ede-Golightly is currently chairman of DeepMatter Group PLC and Oxford Advanced Surfaces Ltd and a non-executive director at Oxehealth Limited.

In a note to clients, analysts at ‘house’ broker Peel Hunt pointed out that  today’s announcements follow other recent changes to Silence’s management and the board. 

“As a reminder of other recent appointments at Silence, Rob Quinn was appointed CFO from his role as interim CFO (18th April) and Giles Campion was appointed (16th April) Head of R&D and Chief Medical Officer (previously SVP of R&D at Prosena and holding senior roles at Novartis and Albumedix),” they said.

Peel Hunt continues to have its rating and target price for Silence ‘under review’.

In afternoon trading, the shares were 4.3% higher at 73p.

 -- Adds analyst comment, share price -- 

View full SLN profile View Profile

Silence Therapeutics PLC Timeline

Related Articles

1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use